STOCK TITAN

Opko Health (OPK) Stock Price, News & Analysis

OPK NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
15 252 sessions, November 18, 2025 to November 18, 2026
Largest daily move
+33.1% close of July 28, 2026
1-year change
+32% closing prices, November 18, 2025 to November 18, 2026
1-month change
+10.5% closing prices, October 16, 2026 to November 18, 2026

Company Description

OPKO Health, Inc. (NASDAQ: OPK) is a multinational biopharmaceutical and diagnostics company. According to its public disclosures, OPKO seeks to establish positions in large, rapidly growing markets by using its discovery, development and commercialization expertise together with novel and proprietary technologies. The company operates in the pharmaceutical preparation manufacturing industry within the broader manufacturing sector and is listed on the Nasdaq stock market under the ticker OPK.

OPKO describes itself as a biopharmaceutical and diagnostics business with activities that span pharmaceutical products, diagnostic testing and laboratory services, and research and development collaborations. The company reports that it aims to build positions in its chosen markets by combining internal research capabilities, clinical development activities and commercialization experience.

Business Segments and Operations

Based on the company information provided, OPKO operates through pharmaceutical and diagnostics activities. A prior description notes that OPKO’s pharmaceutical segment consists of pharmaceutical operations in multiple countries and pharmaceutical research and development operations. The diagnostics activities include clinical and genomics laboratory operations through BioReference and point-of-care operations.

OPKO has stated that its diagnostics segment has generated a significant portion of its revenue. BioReference Health, a wholly owned subsidiary of OPKO, provides clinical testing services. OPKO has also disclosed that BioReference continues to operate core clinical testing services in the New York and New Jersey region and the 4Kscore® Test franchise following the sale of certain oncology and related clinical assets.

Biopharmaceutical and Diagnostics Focus

OPKO characterizes itself as a biopharmaceutical company engaged in the development of therapeutic candidates and vaccines, often through collaborations. For example, the company has reported collaborations involving an Epstein-Barr virus vaccine candidate being developed with Merck, and multispecific antibody programs being advanced through ModeX Therapeutics, an OPKO Health company. These activities reflect OPKO’s stated emphasis on discovery and development of new biologic candidates.

On the diagnostics side, OPKO has highlighted the 4Kscore® Test, which it describes as a blood test indicated for the assessment of the likelihood of aggressive prostate cancer in certain men with elevated or abnormal screening PSA results. The company has reported that the U.S. Food and Drug Administration approved a supplemental application enabling performance of the 4Kscore® Test without digital rectal examination information.

ModeX Therapeutics and Multispecific Antibodies

ModeX Therapeutics Inc. is described as a clinical-stage biopharmaceutical company and an OPKO Health company. ModeX focuses on multispecific biologics for cancer and infectious disease. According to ModeX disclosures, its platforms are designed to unite multiple biologic functions in a single molecule to create multispecific antibodies and vaccines. The ModeX pipeline includes candidates against solid and hematologic tumors and several viral threats.

ModeX reports that it uses a platform known as ModeX Synergistic Targeting of Antibody Receptors (MSTAR) to generate multispecific antibodies from modular building blocks. These multispecific antibodies are intended to address multiple disease pathways simultaneously. ModeX has disclosed clinical programs such as MDX2001, a tetraspecific T cell engager-expander in a Phase 1 trial for advanced solid tumors, and MDX2004, a trispecific antibody-fusion protein being evaluated in a Phase 1/2a study for advanced cancers and immune disorders.

Strategic Collaborations

OPKO has reported multiple collaborations that reflect its stated strategy of using partnerships to advance its technologies. For example, ModeX entered into a license and collaboration agreement with Regeneron Pharmaceuticals to discover and develop multispecific antibodies for several therapeutic indications. Under that agreement, ModeX is eligible for an upfront payment, potential product selection payments, clinical and regulatory milestone payments and commercial milestone payments, as well as tiered royalties on global net sales for selected molecules.

OPKO has also reported a collaboration with Merck on an investigational Epstein-Barr virus vaccine candidate in a Phase 1 trial evaluating safety and tolerability in healthy adults. In addition, OPKO has described collaborations with Entera Bio to develop oral formulations of peptide-based therapies, including an oral dual GLP-1/glucagon tablet candidate (OPK-88006) for obesity and metabolic disorders and an oral GLP-2 tablet for short bowel syndrome and related conditions.

Diagnostics Portfolio and BioReference Health

BioReference Health, a wholly owned subsidiary of OPKO, operates clinical laboratory services. OPKO has reported that BioReference’s continuing operations include core clinical testing in the New York and New Jersey region and the 4Kscore® Test franchise. The company has also disclosed that it completed the sale of BioReference oncology and related clinical assets to Labcorp. According to OPKO, this transaction was intended to streamline BioReference’s laboratory services business and better position the subsidiary to optimize its test menu and pursue sustained profitability.

OPKO’s financial disclosures indicate that the diagnostics segment generates revenue from services, while the pharmaceutical segment generates revenue from products and from the transfer of intellectual property and other sources. The company has noted that changes in diagnostics revenue have been influenced by clinical test volume, asset sales and reimbursement rates, while pharmaceutical revenue has been affected by international operations, product mix, and collaboration-related revenue.

Research and Development Activities

OPKO reports that it invests in research and development to advance early-stage programs and clinical candidates. The company has referenced collaborations supported by the Biomedical Advanced Research and Development Authority (BARDA) for multispecific antibodies for immune-impaired patients at risk for infections such as COVID and influenza. It has also described preclinical and clinical work on GLP-1/glucagon and GLP-2 programs for metabolic and gastrointestinal conditions, often in collaboration with Entera Bio.

ModeX’s programs, including MDX2001, MDX2003 and MDX2004, are part of OPKO’s broader R&D portfolio. The company has reported that these programs are being evaluated in or prepared for clinical trials in oncology and immunology, with data presented at scientific meetings such as the European Society for Medical Oncology (ESMO), the Society for Immunotherapy of Cancer (SITC), and endocrinology and nutrition congresses.

Corporate and Capital Markets Profile

OPKO Health is incorporated in Delaware and its common stock trades on the Nasdaq under the symbol OPK. The company issues periodic financial results and business highlights, and it participates in healthcare investor conferences such as the J.P. Morgan Healthcare Conference and the Piper Sandler Annual Healthcare Conference, where management holds one-on-one meetings with investors and participates in public discussions.

OPKO has disclosed capital markets activities including a share repurchase program authorized by its board of directors and transactions involving its convertible notes. The company reports its financial condition, operating results and significant transactions through quarterly and annual reports and current reports on Form 8-K filed with the U.S. Securities and Exchange Commission.

Position in the Biopharmaceutical and Diagnostics Industry

According to its own descriptions, OPKO aims to build positions in large, rapidly growing markets by combining biopharmaceutical development with diagnostics capabilities. Its activities span therapeutic candidates, vaccines, multispecific antibodies, diagnostics tests and clinical laboratory services. The company’s collaborations with other pharmaceutical and biotechnology firms, as well as its participation in scientific and investor conferences, reflect its role as a participant in the broader biopharmaceutical and diagnostics ecosystem.

Stock Performance

$1.68
-0.59%
-0.01
After hoursChange vs the $1.69 closeLast updated: at
+32%
Performance 1 year

Opko Health (OPK) closed at $1.69 on November 18, 2026. Over the past 12 months, the price has gained 32.0%.

See what a $1,000 investment in OPK would be worth today

Average down calculator for OPK

OPK Metrics & Rankings

Price returns through November 18, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

Opko Health has 10 recent news articles, with the latest published on . Of the recent coverage, 4 articles coincided with positive price movement and 6 with negative movement. Key topics include earnings, earnings date, clinical trial, acquisition, private placement. View all OPK news →

Insider Radar

Net Sellers
90-Day Summary
0
Shares Bought
13,601
Shares Sold
2
Transactions
Most Recent Transaction
PAGANELLI JOHN A (Director) sold 13,601 shares at an average of $1.81 on November 5, 2026

Insider selling at Opko Health over the past 90 days can reflect routine portfolio management, scheduled trading plans (Rule 10b5-1), tax planning, or compensation-related dispositions rather than a directional view on the stock.

Based on SEC Form 4 filings over the last 90 days.

Financial Highlights

Opko Health generated $606.9M in revenue in FY2025, retaining a 33.9% gross margin, operating income reached -$117.4M (-19.4% operating margin), and net income was -$225.7M, reflecting a -37.2% net profit margin. Diluted earnings per share stood at -$0.30. The company generated -$178.5M in operating cash flow. The current ratio was 3.97, measuring current assets divided by current liabilities.

$606.9M
Revenue (FY2025)
-$225.7M
Net Income (FY2025)
-$178.5M
Operating Cash Flow

Upcoming Events

YEAR
2027
2027 Regulatory

RAYALDEE approvals in China

Expect regulatory approvals for RAYALDEE in China and related territories in 2027; may enable sales in Greater China.
YEAR
2044
2044 Financial

Notes maturity

OPKO’s $125M senior secured notes backed by mazdutide royalty interests mature in 2044; payments capped at 1.5x funded amount.

Opko Health has 2 upcoming scheduled events. The next event, "RAYALDEE approvals in China", is expected in 2027. 1 of them is a financing or capital event, such as a dividend or a debt maturity. Investors can track these dates to stay informed about potential catalysts that may affect the OPK stock price.

Short Interest History

Last 12 Months

Short interest in Opko Health (OPK) currently stands at 32.8 million shares, down 3.4% from the previous reporting period, representing 9.0% of the float.

Days to Cover History

Last 12 Months

Days to cover for Opko Health (OPK) currently stands at 9.2 days, up 75.5% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Across the settlements charted above, it has ranged from 5.3 to 17.7 days.

OPK Company Profile & Sector Positioning

Opko Health (OPK) operates in the Diagnostics & Research industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing OPK often look at related companies in the same sector, including Freenome, Inc. (FRNM), Castle Biosciences, Inc. (CSTL), Personalis, Inc. (PSNL), GeneDx Holdings Corp. (WGS), and Fulgent Genetics, Inc. (FLGT). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate OPK's relative position within its industry.

Frequently Asked Questions

The current stock price of Opko Health (OPK) is $1.68 in after-hours trading as of November 18, 2026.

The market cap of Opko Health (OPK) is approximately $1.2B. Learn more about what market capitalization means .

The FY2025 revenue of Opko Health (OPK) is $606.9M, from its most recent completed fiscal year.

The FY2025 net income of Opko Health (OPK) is -$225.7M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Opko Health (OPK) is -$0.30 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Opko Health (OPK) is -$178.5M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The net profit margin of Opko Health (OPK) is -37.2% for FY2025, its most recent completed fiscal year. Learn about profit margins.

The operating profit margin of Opko Health (OPK) is -19.4% for FY2025, its most recent completed fiscal year. Learn about operating margins.

The gross profit margin of Opko Health (OPK) is 33.9% for FY2025, its most recent completed fiscal year. Learn about gross margins.

The current ratio of Opko Health (OPK), current assets divided by current liabilities, was 3.97 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The gross profit of Opko Health (OPK) is $205.9M for FY2025, its most recent completed fiscal year.

The operating income of Opko Health (OPK) is -$117.4M for FY2025, its most recent completed fiscal year. Learn about operating income.

OPKO Health describes itself as a multinational biopharmaceutical and diagnostics company. It engages in pharmaceutical and diagnostic development programs and operates clinical and genomics laboratory services through subsidiaries such as BioReference Health.

OPKO Health’s common stock trades on the Nasdaq stock market under the ticker symbol OPK, as indicated in its press releases and SEC filings.

According to company information, OPKO’s activities include pharmaceutical operations and research and development, and diagnostics operations that encompass clinical and genomics laboratory services and point-of-care operations.

ModeX Therapeutics is a clinical-stage biopharmaceutical company described as an OPKO Health company. It focuses on multispecific biologics for cancer and infectious disease, using platforms designed to combine multiple biologic functions in a single molecule.

OPKO has disclosed collaborations such as a license and collaboration agreement between ModeX and Regeneron Pharmaceuticals to develop multispecific antibodies, a collaboration with Merck on an investigational Epstein-Barr virus vaccine candidate, and joint work with Entera Bio on oral GLP-1/glucagon and GLP-2 tablet programs.

OPKO describes the 4Kscoreae Test as a blood test indicated for assessing the likelihood of aggressive prostate cancer in certain men with elevated or abnormal PSA results. The company reports that the U.S. Food and Drug Administration approved a supplemental application allowing the test to be performed without digital rectal examination information.

OPKO’s financial disclosures indicate that the diagnostics segment generates revenue from services, while the pharmaceutical segment generates revenue from product sales and from the transfer of intellectual property and other sources, including collaboration-related revenue.

OPKO has reported that certain multispecific antibody programs for immune-impaired patients at risk for infections such as COVID and influenza are progressing with support from the Biomedical Advanced Research and Development Authority (BARDA), and that revenue from a BARDA contract contributes to its pharmaceutical segment.

OPKO states that it seeks to establish positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise and its novel and proprietary technologies across biopharmaceutical and diagnostics activities.